PE20130781A1 - Agentes terapeuticos 976 - Google Patents

Agentes terapeuticos 976

Info

Publication number
PE20130781A1
PE20130781A1 PE2013000016A PE2013000016A PE20130781A1 PE 20130781 A1 PE20130781 A1 PE 20130781A1 PE 2013000016 A PE2013000016 A PE 2013000016A PE 2013000016 A PE2013000016 A PE 2013000016A PE 20130781 A1 PE20130781 A1 PE 20130781A1
Authority
PE
Peru
Prior art keywords
alkyl group
hydroxiazetidin
azethyl
methylphenoxy
methanone
Prior art date
Application number
PE2013000016A
Other languages
English (en)
Inventor
Susanne Doris Margit Bokman-Winiwarter
Marlene Fredenwall
Anders Carl Hogner
Lars Anders Mikael Johansson
Robert Andrew Judkins
Lanna Li
Bjorn Christian Ingvar Lofberg
Unge Per Oskar Sverker Von
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130781(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20130781A1 publication Critical patent/PE20130781A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE R1 ES H, F, CIANO, GRUPO ALQUILO C1-C4, ENTRE OTROS; R2 ES H, F; R4 ES -NRaRb, Ra y Rb SON CADA UNA H, GRUPO ALQUILO C1-C4 OPCIONALMENTE SUSTITUIDO CON F, HIDROXI, GRUPO ALCOXI C1-C4.; R5 ES H, GRUPO ALQUILO C1-C3 OPCIONALMENTE SUSTITUIDO CON F, HIDROXI, GRUPO ALCOXI C1-C4; R6 Y R7 SON CADA UNA H, CLORO, GRUPO ALQUILO C1-C4, ENTRE OTROS; A ES O, S. SON COMPUESTOS PREFERIDOS: (3-(4-((3-ETIL-3-HIDROXIAZETIDIN-1-IL)METIL)-2-METILFENOXI)AZETIDIN-1-IL)(5-FENIL-1,3,4-OXADIAZOL-2-IL)METANONA, (3-(4-((3-ETIL-3-HIDROXIAZETIDIN-1-IL)METIL)-3-METILFENOXI)AZETIDIN-1-IL)(5-FENIL-1,3,4-OXADIAZOL-2-IL)METANONA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO Y UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO Y LA PROFILAXIS DE ENFERMEDADES RELACIONADAS CON LA HORMONA CONCENTRADORA DE MELANINA.
PE2013000016A 2010-07-06 2011-07-04 Agentes terapeuticos 976 PE20130781A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36158510P 2010-07-06 2010-07-06

Publications (1)

Publication Number Publication Date
PE20130781A1 true PE20130781A1 (es) 2013-07-20

Family

ID=44514822

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000016A PE20130781A1 (es) 2010-07-06 2011-07-04 Agentes terapeuticos 976

Country Status (26)

Country Link
US (1) US8546375B2 (es)
EP (1) EP2590969B1 (es)
JP (1) JP5827683B2 (es)
KR (1) KR20130041177A (es)
CN (1) CN103209979B (es)
AR (1) AR082113A1 (es)
AU (1) AU2011275547B2 (es)
BR (1) BR112013000296A2 (es)
CA (1) CA2802832A1 (es)
CL (1) CL2013000027A1 (es)
CR (1) CR20130005A (es)
CU (1) CU20130004A7 (es)
DO (1) DOP2013000004A (es)
EA (1) EA201291384A1 (es)
EC (1) ECSP13012369A (es)
ES (1) ES2527466T3 (es)
GT (1) GT201300006A (es)
HK (1) HK1182712A1 (es)
MX (1) MX2012015102A (es)
NI (1) NI201200196A (es)
PE (1) PE20130781A1 (es)
SA (1) SA111320581B1 (es)
SG (1) SG186275A1 (es)
TW (1) TW201206916A (es)
UY (1) UY33487A (es)
WO (1) WO2012004588A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CN104974106B (zh) * 2014-04-04 2019-02-22 浙江普洛康裕制药有限公司 5-烷基-[1,3,4]-噁二唑-2-甲酸烷基酯的合成方法
CN108840812B (zh) * 2018-06-29 2020-08-18 南京富润凯德生物医药有限公司 一种3-(二氟甲基)-3-羟基氮杂环丁烷中间体及其盐的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4212867A (en) * 1977-03-03 1980-07-15 Philagro 2-Cyano-5-substituted 1,3,4-oxadiazoles and fungicidal compositions containing them
DE3039087A1 (de) 1980-10-16 1982-05-19 Hoechst Ag, 6000 Frankfurt 1-(1,3-dioxolan-2-ylmethyl)-azole, ihre salze, verfahren zu ihrer herstellung und ihre verwendung
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB2184122B (en) 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
EP0619814A1 (en) 1991-12-31 1994-10-19 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
MX9702380A (es) 1995-08-02 1998-02-28 Uriach & Cia Sa J Nuevas carboxamidas con actividad antifungica.
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
WO2004011440A1 (ja) 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
EP1593667A4 (en) 2003-02-12 2009-03-04 Takeda Pharmaceutical AMINE DERIVATIVE
US20060293298A1 (en) 2003-04-10 2006-12-28 Bamford Mark J Compounds
GB0400193D0 (en) 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
WO2005066132A1 (en) 2004-01-07 2005-07-21 Astrazeneca Ab Therapeutic agents i
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
TW200538098A (en) 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1786790B1 (en) 2004-07-26 2009-06-03 Eli Lilly And Company Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
PL1805169T3 (pl) 2004-10-18 2009-05-29 Lilly Co Eli Inhibitory receptora histaminowego H3, ich wytwarzanie i zastosowania terapeutyczne
DE602005009021D1 (de) 2004-12-17 2008-09-25 Lilly Co Eli Neue mch-rezeptorantagonisten
WO2006068594A1 (en) 2004-12-21 2006-06-29 Astrazeneca Ab HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
WO2006130075A1 (en) 2005-05-31 2006-12-07 Astrazeneca Ab Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
EP1899296B1 (en) * 2005-06-22 2010-11-17 Pfizer Products Inc. Histamine-3 receptor antagonists
EP1907398A1 (en) 2005-07-15 2008-04-09 AstraZeneca AB Therapeutic agents
UY30079A1 (es) 2006-01-06 2007-08-31 Astrazeneca Ab Compuestos
WO2008011453A2 (en) 2006-07-20 2008-01-24 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
JP2010501553A (ja) 2006-08-18 2010-01-21 アストラゼネカ アクチボラグ Ｍｃｈｒ１アンタゴニストとしてのチエノピリミジン−４−オン誘導体およびチエノピリダジン−７−オン誘導体
CA2664112C (en) 2006-12-05 2015-02-17 Janssen Pharmaceutica N.V. Novel substituted diaza-spiro-pyridinone derivatives for use in mch-1 mediated diseases
US8049013B2 (en) * 2006-12-14 2011-11-01 Eli Lilly And Company 5- [4-(azetidin-3-yloxy)-phenyl]-2-phenyl-5H-thiazolo[5,4-C] pyridin-4-one derivatives and their use as MCH receptor antagonists
WO2008131103A2 (en) 2007-04-17 2008-10-30 Vertex Pharmaceuticals Incorporated Drug discovery methods for aurora kinase inhibitors
ES2400104T3 (es) 2007-07-31 2013-04-05 Vertex Pharmaceuticals Incorporated Proceso para preparación de 5-fluoro-1H-pirazolo[3,4-b]piridin-3-amina y derivados de la misma
WO2009024502A1 (en) 2007-08-22 2009-02-26 F. Hoffmann-La Roche Ag Pyrrolidine aryl-ether as nk3 receptor antagonists
RU2477720C2 (ru) * 2007-10-17 2013-03-20 Санофи-Авентис Замещенные n-фенилбипирролидинкарбоксамиды и их применение в лечебных целях
US8124636B2 (en) 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
JP5780954B2 (ja) * 2008-05-08 2015-09-16 エヴォテック・アクチエンゲゼルシャフト ヒスタミンｈ３受容体アンタゴニストとしてのアゼチジン類及びシクロブタン類
SA110310332B1 (ar) * 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
US9006232B2 (en) 2009-08-13 2015-04-14 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives
US9051296B2 (en) * 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers

Also Published As

Publication number Publication date
TW201206916A (en) 2012-02-16
CU20130004A7 (es) 2013-05-31
MX2012015102A (es) 2013-05-01
AU2011275547B2 (en) 2015-10-29
WO2012004588A3 (en) 2012-08-09
EP2590969A2 (en) 2013-05-15
JP2013535413A (ja) 2013-09-12
UY33487A (es) 2012-02-29
JP5827683B2 (ja) 2015-12-02
AR082113A1 (es) 2012-11-14
GT201300006A (es) 2014-11-06
DOP2013000004A (es) 2013-04-30
ES2527466T3 (es) 2015-01-26
CL2013000027A1 (es) 2013-03-08
SA111320581B1 (ar) 2014-06-17
BR112013000296A2 (pt) 2019-09-24
EP2590969B1 (en) 2014-10-15
CN103209979A (zh) 2013-07-17
CA2802832A1 (en) 2012-01-12
US8546375B2 (en) 2013-10-01
AU2011275547A1 (en) 2013-02-07
EA201291384A1 (ru) 2013-07-30
KR20130041177A (ko) 2013-04-24
CN103209979B (zh) 2016-02-10
CR20130005A (es) 2013-04-17
HK1182712A1 (en) 2013-12-06
US20120010189A1 (en) 2012-01-12
SG186275A1 (en) 2013-01-30
ECSP13012369A (es) 2013-01-31
NI201200196A (es) 2013-10-16
WO2012004588A2 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20070833A1 (es) Compuestos de pirimidinil benzotiofeno
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
CY1108908T1 (el) Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4
EA201171197A1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20081878A1 (es) Compuestos derivados de 1-(4-hidroxifenil sustituido)-4-ol-indazol
PE20142400A1 (es) Compuestos novedosos
PE20160691A1 (es) Nuevos derivados de triazolo[4,5-d]pirimidina
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20110409A1 (es) Compuestos heterociclicos antiviricos
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
PE20142186A1 (es) Derivados biciclicos de pirazinona
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20140934A1 (es) Derivados de pirazol
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
PE20090435A1 (es) Inhibidores de tetrahidropiranocromeno de gamma secretasa

Legal Events

Date Code Title Description
FD Application declared void or lapsed